Literature DB >> 7790030

Development of grafted gld cells in athymic and euthymic recipients.

N Rosenblatt1, K U Hartmann, F Loor.   

Abstract

Mice homozygous for the gld (generalized lymphoproliferative disease) and lpr (lymphoproliferation) mutations display similar autoimmune and lymphoproliferative diseases. Both result from defective apoptosis, the targets of the lpr and gld mutations being the genes for, respectively, an apoptosis-signalling receptor [the Fas antigen receptor (FasR)] and its counter-receptor [the Fas ligand (FasL)]. Though this definitely causes the development and accumulation of large numbers of unusual Thy-1+ B220+ cells in peripheral lymphoid organs, details on how this actually occurs are still lacking. Whether differentiation of gld T cells into Thy-1+ B220+ cells might depend on the environment was analysed by phenotyping the cells which expanded in four different immunodeficient environments (nubg, nulpr, scid and scidbg). Though all four types of congenic chimeras developed hyperglobulinaemia, autoimmunity and a lymphoproliferative disease, substantial differences were found for the athymic and euthymic chimeras. In the athymic gld chimeras, the lymphoproliferation concerned all cell subsets, whereas in the euthymic gld chimeras it was, as in gld mice, due to the accumulation of cells of the Thy-1+ B220+ subset. Thus, the gld T cells could proliferate without differentiating into the Thy-1+ B220+ subset, but this depended on the nature of the environment. Furthermore, emergence of a gld syndrome in these four environments would suggest that B cells and stromal cells do not express FasL, at least in levels sufficient to compensate for the deficiency of the grafted gld cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790030      PMCID: PMC1415155     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  36 in total

1.  The function of antigen-presenting cells in mice with severe combined immunodeficiency.

Authors:  A A Czitrom; S Edwards; R A Phillips; M J Bosma; P Marrack; J W Kappler
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

2.  The C57BL/6 nude, beige mouse: a model of combined T cell and NK effector cell immunodeficiency.

Authors:  F Pflumio; P Fonteneau; C Gavériaux; S Cammisuli; F Loor
Journal:  Cell Immunol       Date:  1989-04-15       Impact factor: 4.868

3.  Mechanisms of marrow graft rejection in murine model systems.

Authors:  G Dennert; C Knobloch; B Yankelevich
Journal:  Transplant Proc       Date:  1987-12       Impact factor: 1.066

4.  Prevention of lymphadenopathy in MRL-lpr/lpr mice by blocking peripheral lymph node homing with Mel-14 in vivo.

Authors:  J D Mountz; W C Gause; F D Finkelman; A D Steinberg
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

5.  The C57BL/6 nu/nu lpr/lpr mouse. II. Pedigree and preliminary characteristics.

Authors:  L Mosbach-Ozmen; P Fonteneau; F Loor
Journal:  Thymus       Date:  1985

6.  Phenotypic, functional, and molecular genetic comparisons of the abnormal lymphoid cells of C3H-lpr/lpr and C3H-gld/gld mice.

Authors:  W F Davidson; F J Dumont; H G Bedigian; B J Fowlkes; H C Morse
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

7.  The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function.

Authors:  J C Roder
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

8.  A severe combined immunodeficiency mutation in the mouse.

Authors:  G C Bosma; R P Custer; M J Bosma
Journal:  Nature       Date:  1983-02-10       Impact factor: 49.962

9.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.

Authors:  T Takahashi; M Tanaka; C I Brannan; N A Jenkins; N G Copeland; T Suda; S Nagata
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

10.  Growth and differentiation in vitro of the accumulating Lyt-2-/L3T4- subset in lpr mice.

Authors:  R C Budd; H R MacDonald; J W Lowenthal; J L Davignon; S Izui; J C Cerottini
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.